Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using its DehydraTECH technology in Delivering Antiviral Drugs

(TheNewswire)

Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 Applications

Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today provides an update on a previously announced antiviral research initiative and introduces a new research project with potential COVID-19 applications

On March 19 2020, Lexaria announced that it planned to conduct a pilot human pharmacokinetic exploratory study in healthy volunteers of antiviral drugs that have previously been studied against other coronavirus strains, comparing Lexaria’s DehydraTECH TM formulations to controls without Lexaria’s technology.

The ethics board approval required as a first step in this pilot study has now been received, conditional on further government regulatory approval also being granted. Lexaria will now begin the process of pursuing the necessary steps to file for approval from federal regulators.

In parallel with this, Lexaria is also announcing

Read More